DNA polymerase ζ regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance

Cancer Research

Volumn 64, Issue 21, 2004, Pages 8029-8035

  Wu, Fang ^a   Lin, Xinjian ^a   Okuda, Tsuyoshi ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA DIRECTED DNA POLYMERASE GAMMA; LUCIFERASE; MESSENGER RNA; PLATINUM;

ARTICLE; CATALYSIS; CATALYST; CELL POPULATION; CELL SURVIVAL; CHROMOSOME ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DEGRADATION; ENZYME REGULATION; GENE EXPRESSION; GENE STRUCTURE; GENETIC VARIABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MUTAGENICITY; PLASMID; PRIORITY JOURNAL; REDUCTION KINETICS; SENSITIVITY ANALYSIS; SEQUENCE HOMOLOGY;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA; DNA-BINDING PROTEINS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; HUMANS; PLATINUM; RECOMBINATION, GENETIC; RNA, MESSENGER;

EID: 7444233763     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3942     Document Type: Article

References (45)

1. Friedberg EC, Feaver WJ, Gerlach VL. The many faces of DNA polymerases: Strategies for mutagenesis and for mutational avoidance. Proc Natl Acad Sci USA 2000;97:5681-3.
2. Lawrence C, Hinkle D. DNA polymerase zeta and the control of DNA damage induced mutagenesis in eukaryotes. Cancer Surveys 1996;28:21-31.
3. Gibbs PEM, McGregor WB, Maher VM, Nisson P, Lawrence CW. A human homolog of the Saccharomyces cervisiae REV3 gene which encodes the catalytic subunit of DNA polymerase. Proc Natl Acad Sci USA 1998;95:6876-80.
4. Yarema KJ, Wilson JM, Lippard SJ, Essigmann JM. Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs. J Mol Biol 1994;236:1034-48.
5. Yarema KJ, Lippard SJ, Essigmann JM. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). Nucleic Acids Res 1995;23:4066-72.
6. Johnson NP, Hoeschele JD, Rahn RO, O'Neill JP, Hsie AW. Mutagenicity, cytotoxicity, and DNA binding of platinum (II)- chloroammines in Chinese hamster ovary cells. Cancer Res 1980;40:1463-8.
7. Wiencke JK, Cervenka J, Paulus H. Mutagenic activity of anticancer agent cisdichlorodiammine platinum-II. Mutat Res 1979;68:69-77.
8. Turnbull NC, Popescu JA, DiPaolo JA, Myhr BC. cis-platinum (II) diamine dichloride causes mutation, transformation, and sister-chromatid exchanges in cultured mammalian cells. Mutat Res 1979;66:267-75.
9. Cariello NF, Swenberg JA, Skopek TR. In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene Cancer Res 1992;52:2866-73.
10. Lin X, Howell SB. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine, and paclitaxel-resistant variants after exposure to cisplatin. Mol Pharmacol 1999;56:390-5.
11. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 2001;61:1508-16.
12. Tofilon PJ, Vines CM, Baker FL, Deen DF, Brock WA. cis- Diamminedichloroplatinum(II)-induced sister chromatid exchange: an indicator of sensitivity and heterogeneity in primary human tumor cell cultures. Cancer Res 1986;46:6156-9.
13. Saburi Y, Nakagawa M, Ono M, et al. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res 1989;49:7020-5.
14. Crul M, Schellens JH, Beijnen JH, Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat. Rev 1997;23:341-66.
15. Chaney SG, Vaisman A. Specificity of platinum-DNA adduct repair. J Inorg Biochem 1999;77:71-81.
16. Vaisman A, Lim SE, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts Biochem 1999;38:11026-39.
17. Johnson RE, Washington MT, Prakash S, Prakash L. Bridging the gap: A family of novel DNA polymerases that replicate faulty DNA. Proc Natl Acad Sci USA 1999;96:12224-6.
18. Hoffmann JS, Pillaire MJ, Lesca C, et al. Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates. Proc Natl Acad Sci USA 1997;93:13766-9.
19. Li Z, Zhang H, McManus TP, McCormick JJ, Lawrence CW, Maher VM. hREV3 is essential for error-prone translesion synthesis past UV or benzo[a]pyrene diol epoxide-induced DNA lesions in human fibroblasts. Mutat Res 2002;510:71-80.
20. Diaz M, Watson NB, Turkington G, Verkoczy LK, Klinman NR, McGregor WG. Decreased frequency and highly aberrant spectrum of ultraviolet-induced mutations in the hprt gene of mouse fibroblasts expressing antisense RNA to DNA polymerase zeta. Mol Cancer Res 2003;1:836-47.
21. Glaab WE, Tindall KR. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 1997;18:1-8.
22. Cenni B, Kim HK, Bubley GJ, et al. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer 1999;80:699-704.
23. Eastman A, Schulte N. Enhanced DNA repair as a mechanisms of resistance to cis-diamminedichloro-platinum(II). Biochem J 1988;27:4730-4.
24. Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002;62:6559-65.
25. Slebos RJ, Taylor JA. A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines. Biochem Biophys Res Commun 2001;281:212-9.
26. Xiao W, Rathgeber L, Fontaine T, Bawa S, Kohalmi, L. REV. 3 is required for spontaneous but not methylation damage-induced mutagenesis of Saccharomyces cerevisiae cells lacking O6-methylguanine DNA methyltransferase. Mutat Res 1999;431:155-65.
27. Zhu F, Jin XC, Song T, Yang J, Guo L, Yu YN. Response of human REV3 gene to gastric cancer inducing carcinogen N-methyl-N′-nitro-N-nitrosoguanidine and its role in mutagenesis. World J Gastroenterol 2003;9:888-93.
28. Lin X, Kim HK, Howell SB. The role of DNA mismatch repair in cisplatin mutagenicity. J Inorg Biochem 1999;77:89-93.
29. Djit FJ, Fichtinger-Schepman AMJ, Berends F, Reedijk J. Formation and repair of cisplatin-induced addcts t-o DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 1988;48:6058-62.
30. Johnson SW, Perez RP, Godwin AK, et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 1994;47:689-97.
31. Damia G, Guidi G, D'Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur J Cancer 1998;34:1783-8.
32. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer K, Pommier Y. Transcription coupled-nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-902.
33. Bradley LJ, Yarema KJ, Lippard SJ, Essigmann JM. Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis- diamminedichloroplatinum (II). Biochem 1999;32:982-8.
34. Esposito G, Godindagger I, Klein U, Yaspo ML, Cumano A, Rajewsky K. Disruption of the Rev31-encoded catalytic subunit of polymerase zeta in mice results in early embryonic lethality. Curr Biol 2000;10:1221-4.
35. Bemark M, Khamlichi AA, Davies SL, Neuberger MS. Disruption of mouse polymerase zeta (Rev3) leads to embryonic lethality and impairs blastocyst development in vitro. Curr Biol 2000;10:1213-6.
36. Wittschieben J, Shivji MK, Lalani E, et al. Disruption of the developmentally regulated Rev31 gene causes embryonic lethality. Curr Biol 2000;10:1217-20.
37. Sonoda E, Okada T, Zhao GY, et al. Multiple roles of Rev3, the catalytic subunit of polzeta in maintaining genome stability in vertebrates. EMBO J 2003;22:3188-97.
38. Holbeck SL, Strathern JN. A role for REV3 in mutagenesis during double-strand break repair in Saccharomyces cerevisiae. Genetics 1997;147:1017-24.
39. Zhong Q, Chen C-F, Li S, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999;285:747-50.
40. Stracker TH, Carson CT, Weitzman MD. Adenovirus oncoproteins inactivate the Mre11 Rad50 NBS1 DNA repair complex. Nature (Lond) 2002;418:348-52.
41. Aloyz R, Xu ZY, Bello V, et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 2002;62:5457-62.
42. McHugh P, Spanswick V, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001;2:483-90.
43. Thompson L, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 2001;477:131-53.
44. Keller K, Overbeck-Carrick T, Beck D. Survival and induction of SOS in Escherichia coli treated with cisplatin, UV-irradiation, or mitomycin C are dependent on the function of the RecBC and RecFOR pathways of homologous recombination. Mutat Res 2001;486:21-9.
45. Johnsson A, Byrne P, de Bruin R, Weiner D, Wong J, Los G. Identification of gene clusters differentially expressed during the cellular injury responses (CIR) to cisplatin. Br J Cancer 2001;85:1206-10.